Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Yucai WangPreetesh JainFrederick L LockeMatthew John MaurerMatthew J FrankJavier L MuñozSaurabh DahiyaAmer M BeitinjanehMiriam T JacobsJoseph P McGuirkJulie M VoseAndre H GoyCharalambos AndreadisBrian T HillKathleen A DorritieOlalekan O OluwoleAbhinav DeolJonas PaludoBijal ShahTrent P WangRahul BanerjeeDavid Bernard MiklosAaron P RapoportLazaros LekakisArmin GhobadiSattva S NeelapuYi LinMichael L WangMichael D JainPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.